These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1680523)

  • 1. Effects of administration of dopamine D2 agonist quinpirole on exploratory locomotion.
    Mogenson GJ; Wu M
    Brain Res; 1991 Jun; 551(1-2):216-20. PubMed ID: 1680523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinpirole to the accumbens reduces exploratory and amphetamine-elicited locomotion.
    Mogenson GJ; Wu M
    Brain Res Bull; 1991 Nov; 27(5):743-6. PubMed ID: 1684529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of quinpirole in the nucleus accumbens depending on the initial level of locomotor activity.
    Wu M; Brudzynski SM; Mogenson GJ
    Brain Res Bull; 1993; 32(4):395-8. PubMed ID: 8106125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemispheric asymmetry in behavioral response to D1 and D2 receptor agonists in the nucleus accumbens.
    Belcheva I; Bryer JB; Starkstein SE; Honig M; Moran TH; Robinson RG
    Brain Res; 1990 Nov; 533(2):286-91. PubMed ID: 1981170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction of dopamine and glutamate in the nucleus accumbens in the regulation of locomotion.
    Wu M; Brudzynski SM; Mogenson GJ
    Can J Physiol Pharmacol; 1993; 71(5-6):407-13. PubMed ID: 7691389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole.
    Zhou LW; Qin ZH; Weiss B
    Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
    Subramaniam S; Lucki I; McGonigle P
    Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of dopamine D2 agonist quinpirole upon the dorsal immobility response in rats.
    Meyer ME; Meyer ME; Potter TJ; Van Hartesveldt C
    Pharmacol Biochem Behav; 1992 Jun; 42(2):257-9. PubMed ID: 1352900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional potentiation between D1 and D2 dopamine agonists: effects of unilateral intra-accumbens injections on locomotor activity in mice.
    Messier C; Mrabet O; Durkin TP; Destrade C
    Life Sci; 1991; 49(9):PL43-8. PubMed ID: 1678133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microinjection of the D2 agonist quinpirole into the A10 dopamine region blocks amphetamine-, but not cocaine-stimulated motor activity.
    Steketee JD; Kalivas PW
    J Pharmacol Exp Ther; 1992 May; 261(2):811-8. PubMed ID: 1349649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticonvulsant effects of ipsilateral but not contralateral microinjections of the dopamine D2 agonist LY 171555 into the nucleus accumbens of amygdala-kindled rats.
    Wahnschaffe U; Löscher W
    Brain Res; 1991 Jul; 553(2):181-7. PubMed ID: 1681980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing regimen differentiates sensitization of locomotion and mouthing to D2 agonist quinpirole.
    Eilam D; Szechtman H
    Pharmacol Biochem Behav; 1990 Aug; 36(4):989-91. PubMed ID: 1977180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacological responsiveness to the dopamine agonist quinpirole in normal weanlings and in weanling offspring exposed gestationally to cocaine.
    Moody CA; Frambes NA; Spear LP
    Psychopharmacology (Berl); 1992; 108(3):256-62. PubMed ID: 1355920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ; Marshall JF
    Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longlasting consequences of chronic treatment with the dopamine agonist quinpirole for the undrugged behavior of rats.
    Einat H; Szechtman H
    Behav Brain Res; 1993 Mar; 54(1):35-41. PubMed ID: 8099289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biphasic effect of D-2 agonist quinpirole on locomotion and movements.
    Eilam D; Szechtman H
    Eur J Pharmacol; 1989 Feb; 161(2-3):151-7. PubMed ID: 2566488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.